All Stories

  1. Recent progress in cGAS–STING agonist design and mechanisms of cancer immune modulation
  2. Anticancer, anti-inflammatory and antioxidant potential of Schiff base-functionalized 1,2-benzothiazine derivatives
  3. From Dimers to Tetramers in Copper(I) Triazene Complexes: Structural Insights and Catalytic Implications
  4. Copper Depletion in Tumors Boosts Immunotherapy
  5. Balancing Activity and Selectivity in Two‐Electron Oxygen Reduction through First Coordination Shell Engineering in Cobalt Single Atom Catalysts
  6. Harnessing metal complexes to target tumour bioenergetics and metabolic vulnerabilities
  7. A Dual Action Platinum(IV) Complex with Self‐assembly Property Inhibits Prostate Cancer through Mitochondrial Stress Pathway
  8. Beyond cisplatin: New frontiers in metallodrugs for hard-to-treat triple negative breast cancer
  9. Anticancer Ru and Os complexes of N-(4-chlorophenyl)pyridine-2-carbothioamide: Substitution of the labile chlorido ligand with phosphines
  10. Platinum(terpyridine) complexes with N-heterocyclic carbene co-ligands: high antiproliferative activity and low toxicityin vivo
  11. Impact of Coordination Mode and Ferrocene Functionalization on the Anticancer Activity of N-Heterocyclic Carbene Half-Sandwich Complexes
  12. Metal-Based Complexes in Cancer Treatment
  13. Triazolyl- vs Pyridyl-Functionalized N-Heterocyclic Carbene Complexes: Impact of the Pendant N-Donor Ligand on Intramolecular C–C Bond Formation
  14. Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors
  15. Antibacterial metal complexes of o ‐sulfamoylbenzoic acid: Synthesis, characterization, and DFT study
  16. Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  17. Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands
  18. Anthracenyl Functionalization of Half-Sandwich Carbene Complexes: In Vitro Anticancer Activity and Reactions with Biomolecules
  19. Triazolyl‐Functionalized N‐Heterocyclic Carbene Half‐Sandwich Compounds: Coordination Mode, Reactivity and in vitro Anticancer Activity
  20. Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents
  21. Carbon Monoxide is an Inhibitor of HIF Prolyl Hydroxylase Domain 2
  22. Heptadentate, Octadentate, Or Even Nonadentate? Denticity in the Unexpected Formation of an All-Carbon Donor-Atom Ligand in RhIII(Cp*)(Anthracenyl-NHC) Complexes
  23. An account of strategies and innovations for teaching chemistry during the COVID‐19 pandemic
  24. Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide
  25. Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells
  26. High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes
  27. Mustards-Derived Terpyridine–Platinum Complexes as Anticancer Agents: DNA Alkylation vs Coordination
  28. Tracing the anticancer compound [RuII(η6-p-cymene)(8-oxyquinolinato)Cl] in a biological environment by mass spectrometric methods
  29. Breaking the Intracellular Redox Balance with Diselenium Nanoparticles for Maximizing Chemotherapy Efficacy on Patient-Derived Xenograft Models
  30. Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands
  31. Thiourea-Derived Chelating Ligands and Their Organometallic Compounds: Investigations into Their Anticancer Activity
  32. A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor
  33. A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor
  34. Heteroleptic Ruthenium(II) Complexes with Bathophenanthroline and Bathophenanthroline Disulfonate Disodium Salt as Fluorescent Dyes for In-Gel Protein Staining
  35. Potent Inhibition of Thioredoxin Reductase by the Rh Derivatives of Anticancer M(arene/Cp*)(NHC)Cl2Complexes
  36. Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
  37. Synthesis, structure and fluxionality of Co(III) complexes containing chelated sulfate
  38. Design of organoruthenium complexes for nanoparticle functionalization
  39. Comparative solution studies and cytotoxicity of gallium(III) and iron(III) complexes of 3-hydroxy-2(1H)-pyridinones
  40. Periodic DFT modeling and vibrational analysis of silver(I) cyanide complexes of thioureas
  41. Coordination Chemistry of Organoruthenium Compounds with Benzoylthiourea Ligands and their Biological Properties
  42. Structural Modifications of the Antiinflammatory Oxicam Scaffold and Preparation of Anticancer Organometallic Compounds
  43. Anticancer organorhodium and -iridium complexes with low toxicity in vivo but high potency in vitro: DNA damage, reactive oxygen species formation, and haemolytic activity
  44. Synthesis, characterisation and electronic properties of naphthalene bridged disilanes
  45. Correction to “(Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity Toward Biomolecules”
  46. Hybrid compounds from chalcone and 1,2-benzothiazine pharmacophores as selective inhibitors of alkaline phosphatase isozymes
  47. Understanding the interactions of diruthenium anticancer agents with amino acids
  48. A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action
  49. Organoruthenium and -osmium Complexes of 2-Pyridinecarbothioamides Functionalized with a Sulfonamide motif: Synthesis, Cytotoxicity and Biomolecule Interaction
  50. (Pyridin-2-yl)-NHC Organoruthenium Complexes: Antiproliferative Properties and Reactivity toward Biomolecules
  51. Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action
  52. Anticancer metallodrugs: where is the next cisplatin?
  53. Making organoruthenium complexes of 8-hydroxyquinolines more hydrophilic: impact of a novel l-phenylalanine-derived arene ligand on the biological activity
  54. Organometallics in Cancer Treatment—Non-conventional Structures and Modes of Action
  55. Anticancer Ru( η 6 - p -cymene) complexes of 2-pyridinecarbothioamides: A structure–activity relationship study
  56. Ruthenium Anticancer Agents En Route to the Tumor
  57. Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity
  58. Back Cover: Functionalization of Ruthenium(II)(η6 -p -cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies (ChemPlusChem 6/2017)
  59. Functionalization of Ruthenium(II)(η6 -p -cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies
  60. Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os
  61. Ruthenium Anticancer Agents-From Cisplatin Analogues to Rational Drug Design
  62. Synthesis, X-ray structure, spectroscopic (IR, NMR) analysis and DFT modeling of a new polymeric Zinc(II) complex of cystamine, [Zn(Cym-Cym)Cl2]
  63. Cationic Ru(η6-p-cymene) Complexes of 3-Hydroxy-4-pyr(id)ones - Lipophilic Triphenylphosphine as Co-Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents
  64. Anticancer activity of Ru- and Os(arene) compounds of a maleimide-functionalized bioactive pyridinecarbothioamide ligand
  65. Pt(II) pyridinium amidate (PYA) complexes: Preparation and in vitro anticancer activity studies
  66. N-(4-Benzoylphenyl)pyridine-2-carbothioamide
  67. Metal complexes of benzimidazole derived sulfonamide: Synthesis, molecular structures and antimicrobial activity
  68. RuII(η6-p-cymene) Complexes of Bioactive 1,2-Benzothiazines: Protein Binding vs. Antitumor Activity
  69. Half-Sandwich Ruthenium(II) Biotin Conjugates as Biological Vectors to Cancer Cells
  70. Traditional Uses, Phytochemistry, and Pharmacology ofOlea europaea(Olive)
  71. Synthesis and characterization of silver(I) complexes of thioureas and thiocyanate: crystal structure of polymeric (1,3-diazinane-2-thione)thiocyanato silver(I)
  72. Organoruthenium and Osmium Anticancer Complexes Bearing a Maleimide Functional Group: Reactivity to Cysteine, Stability, and Cytotoxicity
  73. Development of anticancer agents: wizardry with osmium
  74. Anticancer Ruthenium(η6-p-cymene) Complexes of Nonsteroidal Anti-inflammatory Drug Derivatives
  75. Aromaticities of azines relative to benzene; a theoretical approach through the dimethyldihydropyrene probe
  76. RutheniumII(η6-arene) Complexes of Thiourea Derivatives: Synthesis, Characterization and Urease Inhibition
  77. Extraction of Pb(II) from water samples by ionic liquid-modified silica sorbents
  78. Aromaticity of azines through dyotropic double hydrogen transfer reaction
  79. Copper Complexes of Bioactive Ligands with Superoxide Dismutase Activity
  80. Solution equilibrium studies on anticancer ruthenium(II)–η6-p-cymene complexes of 3-hydroxy-2(1H)-pyridones
  81. Theoretical insight of polypyrrole ammonia gas sensor
  82. Novel metal(ii) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents
  83. Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes
  84. Organometallic Ruthenium and Osmium Compounds of Pyridin-2- and -4-ones as Potential Anticancer Agents
  85. Biomolecule binding vs. anticancer activity: Reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins
  86. Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules
  87. Synthesis of [RuII(η6-p-cymene)(PPh3)(L)Cl]PF6 complexes with carbohydrate-derived phosphites, imidazole or indazole co-ligands
  88. Pyrone derivatives and metals: From natural products to metal-based drugs
  89. From hydrolytically labile to hydrolytically stable RuII–arene anticancer complexes with carbohydrate-derived co-ligands
  90. Is the Reactivity of M(II)−Arene Complexes of 3-Hydroxy-2(1H)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?
  91. Osmium(ii)–versus ruthenium(ii)–arene carbohydrate-based anticancer compounds: similarities and differences
  92. Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)?(η6-Arene) Complexes
  93. Silver(I) Complexation with Glutathione in the Presence of Tetramethylthiourea
  94. In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands
  95. Bis(cyanido-κC)(ethane-1,2-diamine-κ2N,N′)silver(II)
  96. Poly[bis(μ2-cyanido)-κ2C:N;κ2N:C-(μ2-N,N,N′,N′-tetramethylthiourea-κ2S:S)disilver(I)]